Business Wire

THALES

14.9.2021 09:02:12 CEST | Business Wire | Press release

Share
New Era of Remote Working Calls for Modern Security Mindset, Finds Thales Global Survey of IT Leaders

COVID-19 quickly ushered in the era of remote work, introducing new risks that IT professionals are struggling to manage with existing security tools, according to a new Thales study. Six in 10 respondents said traditional security tools such as VPNs are still the primary vehicle for employees accessing applications remotely -- likely the reason why almost half (44%) were not confident that their access security systems could scale effectively to secure remote work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005014/en/

These are among the key insights from the 2021 Thales Access Management Index , a global survey of 2,600 IT decision makers, commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, to better understand the new security risks and challenges caused by the rise of remote working and cloud transformation caused by the COVID-19 pandemic.

Last year saw a surge in cybercrime exploiting the various aspects of the COVID-19 pandemic and the shift to remote work, with ransomware attacks soaring by 150%.1 The Thales survey found the pandemic’s effects have had a significant impact on security infrastructure, particularly on access management and authentication frameworks, pushing organisations to adopt modern security strategies like Zero Trust to support the demands of a more mobile and remote workforce.

Era of Remote Working – Concerns Catalyse Change

According to the index, respondents have many different systems deployed for remote access. When asked about the technologies that were in place, VPN was the most common, with 60% of IT professionals identifying the capability. Virtual Desktop Infrastructure, cloud-based access and Zero Trust network access/software defined perimeter (ZTNA/SDP) closely followed. However, when asked what new access technologies respondents were planning to deploy due to the pandemic, nearly half (44%) indicated ZTNA/SDP was the top technology choice.

Thales also explored respondents’ plans to move beyond traditional VPN environments, and found that nearly 40% expect to replace their VPN with ZTNA/SDP, while 38% expect to move to a Multi-Factor Authentication (MFA) solution. This confirms the need for more modern, sophisticated authentication capabilities is driving change in many organisations and is perceived as a key enabler of Zero Trust security.

“Seemingly overnight, remote access went from being an exception to the default working model for a large swath of employees. As a result, businesses are navigating a volatile and complex world, and adopting a Zero Trust model of cybersecurity will enable them to continue to conduct operations safely amidst the uncertainty,” said Francois Lasnier, vice president of Access Management solutions at Thales . “One of the core barrier businesses face when starting their Zero Trust journey is the balance between locking down access without interrupting workflow. People require access to sensitive data in order to work and collaborate and businesses leaders will need to ensure that a drop in productivity doesn’t become an unwanted side effect. The research shows that IT professionals increasingly see access management and modern authentication capabilities as key component in achieving a Zero Trust model.”

Room to Grow with Zero Trust

The Thales report found that Zero Trust models are the solution of choice for respondents seeking to improve access environments, yet many are still in the early stage of adoption.

According to the research, less than a third (30%) of the respondents claim to have a formal strategy and have actively embraced a Zero Trust policy. Additionally, almost half (45%) are either planning, researching or considering a Zero Trust strategy. Surprisingly, less than a third (32%) of the respondents indicated that Zero Trust shapes their cloud security strategy to a great extent.

Access Security Needs to Adapt to Deal with Dynamic Workplaces

A silver lining of the pandemic-driven rush to remote working is the acceleration of improved approaches to access security. Thales found that 55% of respondents currently have adopted two-factor authentication within their organisations. Regionally, there was notable variation, with the UK leading (64%), followed by the U.S. (62%), APAC (52%) and LATAM (40%). These varying degrees of adoption may be due to the level at which better access management is prioritised in security investments.

Yet, despite the well-known limitations of passwords, investment in MFA still trails other security tools like firewalls, endpoint security, SIEM and email security. Remote access users are still the main use case for MFA adoption (71%). One-third of respondents that have adopted MFA use more than three different authentication tools, signaling the need for a more unified approach to access management in the future.

“Security tools and approaches need to adapt to better support the era of remote working,” said Eric Hanselman, chief analyst at 451 Research, part of S&P Global Market Intelligence . “The shift towards a Zero Trust model, along with increasing use of modern authentication technologies, like adaptive and multifactor authentication (MFA), will improve organisations’ security posture. This will be an exciting space to watch as businesses continue to deal with dynamic workplace environments.” 2

Thales and 451 Research will discuss the global findings in more detail during its upcoming Trusted Access Summit on 5 October 2021. To join, please visit the registration page .

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

1 Group-IB Ransomware Uncovered 2020-2021
2 Quote from Thales 2021 Global Access Management Index

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye